COMMUNIQUÉS West-GlobeNewswire
-
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
18/05/2026 -
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
18/05/2026 -
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
18/05/2026 -
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
18/05/2026 -
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
18/05/2026 -
ORAGENICS PROVIDES INVESTOR UPDATE
18/05/2026 -
Novastra Therapeutics Appoints Chief Financial Officer as Company Advances Lead Candidate Toward Global Clinical Development
18/05/2026 -
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
18/05/2026 -
Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
18/05/2026 -
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
18/05/2026 -
Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference
18/05/2026 -
CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION
18/05/2026 -
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
18/05/2026 -
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
18/05/2026 -
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer
18/05/2026 -
Alpha Tau to Participate in May Investor Conferences
18/05/2026 -
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
18/05/2026 -
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
18/05/2026 -
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
18/05/2026
Pages